Other Related Topics

Webinars/Videos

• Running time: 35 minutes, 49 seconds

   

  00.16 Lp(a) structure and metabolism

  01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases

  02.38 Factors influencing Lp(a) level

  03.35 Physiological functions of Lp(a)

  04.12 Atherogenicity of Lp(a)

  04.56 Clinical implication of Lp(a) elevation

  05.25 Genetic variants associated with increased Lp(a) concentrations

  05.44 Association between high Lp(a) level and risk of various cardiovascular diseases

  07.43 Clinical implication of Lp(a) elevation at low LDL-C

  08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors

  09.40 Is reducing Lp(a) physiologically safe?

  10.34 Strategies to lower Lp(a) level

  11.57 Future directions in Lp(a) research

  12.37 Summary

  Webinars/Videos

  Lp(a):What is it and its role in atherosclerosis

  In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.

  View

  • Share
• Running time: 58 minutes, 46 seconds

   

  01.28 Concept of cumulated LDL exposure (mg-years)

  05.11 Re-defining secondary prevention

  08.04 Early secondary prevention

  11.27 Late secondary prevention (CHD)

  19.17 Late secondary prevention (PAD)

  20.15 Very late secondary prevention (ACS)

  23.18 Longer is better

  24.55 Earlier is better

  26.21 Younger is better

  28.39 Older Adults also deserve treatment

  41.12 Audience Q&A

  Webinars/Videos

  “Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?

  Prof. Chiang discusses Atherosclerotic Cardiovascular Disease (ASCVD) in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. At 41:12 he answers audience questions.

  View

  • Share